Ephedra

References

• Soni M G, Carabin I G, Griffiths J C, et al. Safety of ephedra: Lessons learned. Toxicol Letters 2004; 150: 97–110
   PubMed Web of Science ®Google Scholar
• Bent S, Tiedt T N, Odden M C, et al. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 138: 468–71
   PubMed Web of Science ®Google Scholar
• Miller S C. Safety concerns regarding ephedrine-type alkaloid containing dietary supplements. Military Med 2004; 169: 87–93
   PubMed Web of Science ®Google Scholar
• Shekelle P G, Hardy M L, Morton S C, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. A meta-analysis. JAMA 2003; 289: 1527–45
   Google Scholar
• Lindsay B D. Are serious adverse cardiovascular events an unintended consequence of the dietary supplement health and education act of 1994?. Mayo Clinic Proceed 2002; 77: 7–9
   PubMed Web of Science ®Google Scholar
• Wooltoron E, Sibbald B. Ephedra/ephedrine: Cardiovascular and CNS effects. Can Med J 2002; 166: 633
   PubMed Web of Science ®Google Scholar
• Kernan W N, Viscoli C M, Brass L M, Broderick J P, Brott T, et al. Phenylpro-panolamine and the risk of hemorrhagic stroke. New Engl J Med 2000; 343(25)1826–32
   PubMed Web of Science ®Google Scholar
• Barnes P, Powell-Griner E, McFann K, Nahin R. Complementary and Alternative Medicine Use Among Adults: United States. CDC Advance Data Report #343, May 27, 2002, 2004
   Google Scholar
• Rhee S M, Garg V K, Hershey C O. Use of complementary and alternative medicines by ambulatory patients. Arch Intern Med 2004; 164: 1004–9
   PubMed Web of Science ®Google Scholar
• Blanck H M, Khan L K, Serdula M K. Use of non-prescription weight loss products: results from a multistate survey. JAMA 2001; 286: 930–5
   PubMed Web of Science ®Google Scholar
• Trigazis L, Tennakore D, Vohra S, et al. The use of herbal remedies by adolescents with eating disorders. Int J Eat Disord 2004; 35: 223–8
   PubMed Web of Science ®Google Scholar
• Flegal K M, Carroll M D, Ogden C L, et al. Prevalence and trends in obesity among U.S. adults, 1999–2000. JAMA 2002; 288: 1723–7
   PubMed Web of Science ®Google Scholar
• Dietary Supplement Health and Education Act of 1994, Available at: http://www.fda.gov/opacom/laws/dshea.html Accessed 7/2/04.
   Google Scholar
• Burdock G A. Dietary supplements and lessons to be learned from GRAS. Regulat Toxicl & Pharmacol 2000; 31: 68–76
   PubMed Web of Science ®Google Scholar
• Fontanarosa P B, Rennie D, DeAngelis C. The need for regulation of dietary supplements-lessons from ephedra. JAMA 2003; 289: 1568–70
   PubMed Web of Science ®Google Scholar
• Hathcock J. Dietary supplements: How are they used and regulated. J Nutrition 2001; 131: 1114s–7s
   PubMed Web of Science ®Google Scholar
• Noonan W P, Noonan C. Legal requirements for “functional food” claims. Toxicology Letters, 150(1)19–24
   PubMed Web of Science ®Google Scholar
• Leape L L. Reporting of adverse events. New Engl J Med 2002; 347: 1633–38
   PubMed Web of Science ®Google Scholar
• Federal Register. Current Good Manufacturing Practice in Manufacturing, Packing, or Holding Dietary Ingredients and Dietary Supplements; a proposed rule, 68 FR 49. 12157–12263. Accessed at http://www.cfsan.fda.gov/∼lrd/fr030313.html. Available 7/29/04.
   Google Scholar
• Anonymous. USP launches dietary supplement certification program. Am J Health Syst Pharm 2002; 59: 232
   PubMed Web of Science ®Google Scholar
• Anonymous. Sports nutrition & weight loss market III. Nutrition Business Journal Feb, 2002; 1–8
   Google Scholar
• Anonymous. Sports nutrition & weight loss market IV. Nutrition Business Journal Oct, 2003; 1–13
   Google Scholar
• Haller C A, Benowitz N L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833–8
   PubMed Web of Science ®Google Scholar
• Boozer C N, Daly P A, Homel P, et al. Herbal ephedra/caffeine for weight loss: A 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord May, 2002; 26(5)593–604
   PubMed Web of Science ®Google Scholar
• Arterburn D E, Crane P K, Veenstra D L. The efficacy and safety of sibutramine for weight loss. A systematic review. Arch Intern Med 2004; 164: 994–1003
   PubMed Web of Science ®Google Scholar
• Hauptman J, Lucas C, Hordin M N, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160–7
   PubMedGoogle Scholar
• Haller C A, Jacob P, Benowitz N L. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther 2002; 71: 421–32
   PubMed Web of Science ®Google Scholar
• Samenuk D, Link M S, Homoud M, et al. Adverse cardiovascular events temporally associated with Ma Huang, an herbal source of ephedrine. May Clin Proceed 2002; 77: 12–6
   PubMed Web of Science ®Google Scholar
• FDA Medical Bulletin. Adverse Events with Ephedra and Other Botanical Dietary Supplements, Available at: http://www.cfsan.fda.gov/∼dms/ds-ephe2.html. Accessed July 29, 2004.
   Google Scholar
• Federal Register. Dietary Supplements Containing Ephedrine Alkaloids, Availability. 65 FR 17. 17510–17512. Accessed at http://www.cfsan.fda.gov/∼lrd/fr00043b. html. Available 7/29/04.
   Google Scholar
• FDA Talk Paper. FDA Warns Against Drug Promotion of “Herbal Fen-Phen.”, Available at http://www.cfsan.fda.gov/∼1rd/tpfenphn.html. Accessed 6/4/04.
   Google Scholar
• Federal Register. Dietary Supplements Containing Ephedrine Alkaloids, Availability. 65 FR 17. 17509–17510. Accessed at http://www.cfsan.fda.gov/∼lrd/fr00043b. html. Available 7/29/04.
   Google Scholar
• Meadows M. Public health officials caution against ephedra use. FDA Consumer May-June, 2003; 8: 9
   Google Scholar
• HHS Press Release. FDA Proposes Safety Measures for Ephedrine Dietary Supplements, Available at: http://www.cfsan.fda.gov/∼lrd/hhsephed.html. Accessed July 6, 2004.
   Google Scholar
• Shekelle P, Morton S, Maglione M, et al. Ephedra and Ephedrine for Weight Loss and Athletic Performance Enhancement: Clinical Efficacy and Side Effects. AHRQ Publication No. 03-E022, Agency for Healthcare Research and Quality, Rockville, MD February, 2003, Available at http://www.fda.gov/OHRMS/DOCKETS/ 98fr/95n-0304-bkg0003-ref-07–01-index.htm. Accessed July 30, 2004., Evidence Report/Technology Assessment No. 76 (Prepared by Southern California Evidence-based Practice Center, RAND, under Contract No 290–97–0001, Task Order No. 9)
   Google Scholar
• , Docket: 95N-0304-Dietary Supplements Containing Ephedrine Alkaloids Comment Number: EC-1365. Available at: http://www.fda.gov/ohrms/dockets/dailys/03/Apr03/041103/95N-0304-EC-1365.htm. Accessed 7/30/04.
   Google Scholar
• Federal Register. Final Rule Declaring Dietary Supplements Containing Ephed-rine Alkaloids Adulterated Because They Present an Unreasonable Risk, 69 FR 28. 6787–6854. Available at http://www.cfsan.fda.gov/∼lrd/fr040211.html. Accessed 7/ 29/04.
   Google Scholar
• Lenz T L, Hamilton W R. Supplemental products used for weight loss. J Am Pharm Assoc 2004; 44: 59–68
   Google Scholar
• Pittler M H, Ernst E. Dietary supplements for body-weight reduction: A systematic review. Am J Clin Nutr 2004; 79: 529–36
   PubMed Web of Science ®Google Scholar
• Pellati F, Benvenuti S, Melegari M, et al. Determination of adrenergic agonists from extracts and herbal products of Citrus aurantium L. var. amara by LC. J Pharm Biomed Anal 2002; 29: 1113–9
   PubMed Web of Science ®Google Scholar
• Preuss H G, DiFerdinando D, Bagchi M, et al. Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: An overview. Journal Medicine 2002; 33: 247–64
   PubMedGoogle Scholar
• Nykamp D L, Fackih M N, Compton A L. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother 2004; 38: 812–6
   PubMed Web of Science ®Google Scholar
• Colker C M, Kalman D S, Torina G C, et al. Effects of Citrus aurantium extract, caffeine, and St John’s Wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res Clin 1999; 60: 145–53
   Web of Science ®Google Scholar
• Kalman D S, Colker C M, Shi Q, et al. Effects of a weight-loss aid in healthy overweight adults: Double-blind, placebo-controlled clinical trial. Curr Ther Res Clin Exp 2000; 61: 199–205
   Web of Science ®Google Scholar
• Guo L Q, Taniguchi M, Chen Q Y, et al. Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: Properties of umbelliferous or citrus crude drugs and their relative prescriptions. Japan Journ Pharmacol 2001; 85: 399–408
   PubMedGoogle Scholar
• Kovacs E M, Lejeune M P, Nijs I, et al. Effects of green tea on weight maintenance after body-weight loss. British J Nutr 2004; 91: 431–7
   PubMed Web of Science ®Google Scholar
• Andersen T, Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Dietet 2001; 14: 243–50
   Google Scholar
• Astrup A, Toubro S, Cannon S, et al. Thermogenic synergism between ephedra and caffeine in healthy volunteers: A double-blind, placebo-controlled study. Metabolism 1991; 40: 323–9
   PubMed Web of Science ®Google Scholar
• Smith A, Brice C, Nash J, et al. Caffeine and central noradrenaline: Effects on mood, cognitive performance, eye movements and cardiovascular function. J Psycho-pharm 2003; 17: 283–92
   PubMed Web of Science ®Google Scholar
• Ernst E, Pittler M H. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159: 433–36
   PubMed Web of Science ®Google Scholar
• Kucio C, Jonderko K, Piskorska D. Does yohimbine act as a slimming drug?. Isr J Med Sci 1991; 27: 550–6
   PubMedGoogle Scholar
• Sax L. Yohimbine does not affect fat distribution in men. Int J Obesity 1991; 15: 561–65
   PubMed Web of Science ®Google Scholar
• Preuss H G, Bagchi D, Bagchi M, et al. Effects of a natural extract of -(-) hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obesity Metab 2004; 6: 171–80
   PubMed Web of Science ®Google Scholar
• Heymsfield S B, Allison D B, Vasselli J R, et al. Garcinia cambogia (Hydroxycitric acid) as a potential antiobesity agent: A randomized controlled trial. JAMA 1998; 280: 1596–1600
   PubMed Web of Science ®Google Scholar
• Pittler M H, Abbot N C, Harkness E F. Randomized, double-blind trial of chitosan for body weight reduction. Europ J Clinical Nutr 1999; 53: 379–81
   PubMed Web of Science ®Google Scholar
• Woodgate D E, Conquer J A. Effects of a stimulant-free dietary supplement on body weight and fat loss in obese adults: A six-week exploratory study. Curr Ther Res Clin Exp 2003; 64: 248–62
   PubMed Web of Science ®Google Scholar
• Lis-Balchin M. Parallel placebo-controlled clinical study of a mixture of herbs sold as a remedy for cellulite. Phytotherapy Res 1999; 13: 627–9
   PubMed Web of Science ®Google Scholar
• Saengsirisuwan V, Kinnick T R, Schmit M B, et al. Interactions of exercise training and lipoic acid on skeletal muscle glucose transport in obese Zucker rats. J Applied Phys 2001; 91: 145–53
   PubMed Web of Science ®Google Scholar
• Pittler M H, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: Meta-analysis of randomized trials. Int J Obesity 2003; 27: 522–9
   PubMed Web of Science ®Google Scholar
• Vincent J B. The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent, and muscle development agent. Sports Med 2003; 33: 213–30
   PubMed Web of Science ®Google Scholar
• Wang J, Yuen V G, McNeill J H. Effect of vandaium on insulin sensitivity and appetite. Metabol Clin & Expirem 2001; 50: 667–74
   PubMed Web of Science ®Google Scholar
• Shao J, Catalano P M, Yamashita H, et al. Vandate enhances but does not normalize glucose transport and insulin receptor phosphorylation in skeletal muscle from obese women with gestational diabetes mellitus. Am J Obstet Gynecol 2000; m183: 12653–9
   Google Scholar
• Bays H, Dujovne C. Pharmacotherapy of obesity. Currently marketed and upcoming agents. Am J Cardiovasc Drugs 2002; 2: 245–53
   PubMedGoogle Scholar
• Gurley B J, Gardner S F, Hubbard N A. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm 2000; 57: 962–9
   Google Scholar
• FDA Press Release. FDA/CFSAN SN/AEMS removed, http://www.cfsan.fda.gov/∼dms/aems.html. Accessed August 16, 2004.
   Google Scholar
• Schulman S. Addressing the potentials risks associated with ephedra use: A review of recent events. Public Health Reports 2003; 118: 487–92
   PubMed Web of Science ®Google Scholar
• Federal Register. Dietary Supplements; Strategy for the further implementation and enforcement of the Dietary Supplement Health and Education Act of 1994, Availability. 69 FR 216. 64957–8. Available at http://www.cfsan.fda.gov/∼lrd/fr04119a. html. Accessed 2/3/05.
   Google Scholar
• FDA Consumer Magazine. Regulatory Initiatives for Dietary Supplements. January-February, 2005, Available at http://www.fda.gov/fdac/features/2005/105_diet.html. Accessed 2/3/05
   Google Scholar
• Hampton T. More Scrutiny for Dietary Supplements. JAMA 2005; 293: 27–8
   PubMed Web of Science ®Google Scholar
• Hampton T. More scrutiny for dietary supplements. JAMA 2005; 293: 278
   Google Scholar
• Order. Nutrceutical Corp vs Crawford. Case No. 2:04CV409 TC, 2005, Available at http:www.utd.uscourts.gov/reports/204cv409–28.pdf. Assessed 5/6/05.
   Google Scholar